Related Experiment Video

Updated: Jul 2, 2025

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.2K

Effectiveness of trabectedin for radiation-induced angiosarcoma of the breast refractory to several anticancer drugs

Erina Matsuzaki1, Ikko Kajihara1, Mai Tomiguchi2

  • 1Department of Dermatology and Plastic Surgery, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.

The Journal of Dermatology
|February 17, 2024
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Stereotactic Radiosurgery for Gynecologic Cancer
10:35

Stereotactic Radiosurgery for Gynecologic Cancer

Published on: April 17, 2012

18.2K
Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients
05:31

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients

Published on: September 20, 2020

5.6K

Related Experiment Videos

Last Updated: Jul 2, 2025

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.2K
Stereotactic Radiosurgery for Gynecologic Cancer
10:35

Stereotactic Radiosurgery for Gynecologic Cancer

Published on: April 17, 2012

18.2K
Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients
05:31

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients

Published on: September 20, 2020

5.6K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K

Articles linked to this work by shared authors, journal, and citation graph.

IL-12-producing iPSC-derived antigen-presenting cells enhance antitumor immunity and enable off-the-shelf immunotherapy.

Molecular therapy : the journal of the American Society of Gene Therapy·2026

Upregulated ST2L-Dependent IL-33 Signaling in Dermal Fibroblasts Contributes to IL-6 Induction and Skin Fibrosis in Systemic Sclerosis.

The Journal of dermatology·2026

Dermatological Needs After the 2026 Kumamoto Earthquake.

The Journal of dermatology·2026

Anterior gradient 2 is overexpressed in extramammary Paget's disease and involved in cell survival.

Journal of dermatological science·2026

The mechanism of malignant progression in extramammary Paget's disease (EMPD): hallmarks of EMPD.

Medical molecular morphology·2026

Aging-related IgG accumulation promotes skin inflammation.

The Journal of investigative dermatology·2026

Hypogammaglobulinemia and Infection After Rituximab in Pemphigus, With Divergent Desmoglein Antibody and Immunoglobulin Kinetics: A Retrospective Cohort Study.

The Journal of dermatology·2026

Ten-Year Longitudinal Changes in Nailfold Videocapillaroscopy Findings and Clinical Features in Systemic Sclerosis.

The Journal of dermatology·2026

Secukinumab for Refractory Psoriasiform Cutaneous Manifestations in CTSC-Syndromic Epidermal Differentiation Disorder: A Pediatric Case Report.

The Journal of dermatology·2026

Immune Responses Associated With Nephritis-Associated Plasmin Receptor in IgA Vasculitis.

The Journal of dermatology·2026

Treatment Satisfaction and Patterns Among Primary Hyperhidrosis Patients.

The Journal of dermatology·2026

Global Molecular Epidemiology and Genotype-Phenotype Correlations in Keratinocytic Epidermal Nevus: A Systematic Review.

The Journal of dermatology·2026

Time to Treatment Failure as a Recorded Treatment-Process Measure in C-CAT. Reply to Comment on "Facility-Level Medical Oncology Specialist Availability and First-Line Time to Treatment Failure in Lung Cancer: A Nationwide C-CAT Registry Analysis. Curr. Oncol. 2026, 33, 462".

Current oncology (Toronto, Ont.)·2026

Does Time to Treatment Failure Measure the Same Clinical Process Across Oncology Facilities? Comment on Kajiura et al. Facility-Level Medical Oncology Specialist Availability and First-Line Time to Treatment Failure in Lung Cancer: A Nationwide C-CAT Registry Analysis. Curr. Oncol. 2026, 33, 462.

Current oncology (Toronto, Ont.)·2026

Electroacupuncture Combined with Cognitive Behavioral Therapy for Insomnia Alleviates Insomnia-Anxiety Comorbidity in Gynecological Cancer Patients Undergoing Chemotherapy: A Randomized Controlled Trial.

Current oncology (Toronto, Ont.)·2026

[177Lu]Lu-PSMA-617 in Metastatic Hormone-Sensitive Prostate Cancer: Evidence from PSMAddition and Considerations for Treatment Sequencing.

Current oncology (Toronto, Ont.)·2026

A New Era of Treatment Sequencing in Platinum-Resistant Ovarian Cancer: Integrating Immunotherapy, Antibody-Drug Conjugates, and Targeted Therapies.

Current oncology (Toronto, Ont.)·2026

A Remotely Delivered Exercise-Based Rehabilitation Program for Patients with Persistent Chemotherapy-Induced Peripheral Neuropathy (EX-CIPN): A Phase I Feasibility Trial.

Current oncology (Toronto, Ont.)·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us